03:25 PM EDT, 04/10/2025 (MT Newswires) -- Incyte ( INCY ) faces limited exposure to tariffs with dual sourcing for key products in the Europe and US, UBS said Wednesday in a report.

The large molecule production facility is in Switzerland, combined with investments in US manufacturing capacity, leaves Incyte ( INCY ) "relatively less exposed to policy and

regulatory risks weighing on the rest of the biopharma sector," the report said.

UBS estimated Q1 sales of $103 million on Opzelura, used to treat atopic dermatitis, trailing the consensus forecast of $131 million. The bank's projection on Jakafi, containing ruxolitinib used to treat certain blood cancers, rose to $640 million from $606 million, compared with the consensus $643 million.

Results from Q1 are expected April 29.

UBS maintained its neutral rating on Incyte ( INCY ) stock and reduced the price target to $61 from $69, partly citing "a lack of meaningful pipeline catalysts."

Incyte ( INCY ) shares fell 5.3% in recent Thursday trading.

Price: 55.72, Change: -3.14, Percent Change: -5.33